Three biotechs line up for IPOs amid market skittishness

A trio of small drug developers are queuing up to go public as the years-long open window for biotech IPOs continues to falter. Viventia Bio, developing treatments for cancer, and Kura Oncology each filed to raise $86 million, while Dutch oncology biotech Merus lined up for a $60 million debut. Meanwhile, most of the past month's biotech debutantes have priced their IPOs at significant discounts, as marketwide concerns about drug pricing and R&D success have driven down valuations across the biopharma industry. Viventia | Kura | Merus

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.